Jeff Michalski, MD, MBA

Radiation Oncologist

Primary Academic Title

Carlos A. Perez Distinguished Professor and Vice Chair of Radiation Oncology, Washington University School of Medicine

Clinical Expertise

Prostate, kidney and bladder cancer; pediatric cancer; sarcoma; prostate brachytherapy

Research Interest

Pediatric radiation oncology, conformal radiotherapy, radiation oncology, quality assurance, genitourinary radiation oncology. Key words: Genitourinary cancer, prostate cancer, radiation therapy, IMRT, conformal, radiation, dose escalation, tate effects, pediatric cancer, medulloblastoma, normal tissue effect modeling, quality of life, clinical trials.

Education

1986: MD, Medical College of Wisconsin, Milwaukee

Training

1986 - 1988: Resident, internal medicine and radiation oncology, Columbia-Presbyterian Medical Center, New York
1988 - 1990: Resident, radiation oncology, Washington University, St. Louis
1990 - 1991: Clinical instructor/fellow, radiation oncology, Washington University

Board Certification

1991: American Board of Radiology, Radiation Oncology

Selected Research Publications

Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.

Dahl DM, Rodgers JP, Shipley WU, [...] Michalski JM, [...] Efstathiou JA
J Clin Oncol 2024

Quantitative 68Ga-PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial).

Kuo PH, Morris MJ, Hesterman J, [...] Michalski JM, [...] Herrmann K
Radiology 2024

Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

Lee WR, Dignam JJ, Amin MB, [...] Michalski JM, [...] Sandler HM
J Clin Oncol 2024

Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.

Buyyounouski MK, Pugh SL, Chen RC, [...] Michalski JM, [...] Sandler HM
JAMA Oncol 2024

NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.

Flaig TW, Spiess PE, Abern M, [...] Michalski J, [...] Gurski LA
J Natl Compr Canc Netw 2024

Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer.

Chi KN, Armstrong AJ, Krause BJ, [...] Michalski JM, [...] Tagawa ST
Eur Urol 2024

Effects of Androgen Deprivation Therapy on Prostate Cancer Outcomes According to Competing Event Risk: Secondary Analysis of a Phase 3 Randomised Trial.

Mell LK, Pugh SL, Jones CU, [...] Michalski JM, [...] Feng F
Eur Urol 2024

Beyond Average: α-Particle Distribution and Dose Heterogeneity in Bone Metastatic Prostate Cancer.

Benabdallah N, Lu P, Abou DS, [...] Michalski J, [...] Thorek DLJ
J Nucl Med 2024

Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate.

Roy S, Romero T, Michalski JM, [...] Kishan AU
J Clin Oncol 2023

The Importance of Quality Assurance in Radiation Oncology Clinical Trials.

FitzGerald TJ, Bishop-Jodoin M, Laurie F, [...] Michalski J
Semin Radiat Oncol 2023

Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.

Michalski JM, Winter KA, Prestidge BR, [...] Sandler HM
J Clin Oncol 2023

Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.

Sartor O, Karrison TG, Sandler HM, [...] Michalski JM, [...] Rosenthal SA
Eur Urol 2023

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial.

Krauss DJ, Karrison T, Martinez AA, [...] Michalski JM, [...] Sandler HM
J Clin Oncol 2023

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial.

Movsas B, Rodgers JP, Elshaikh MA, [...] Michalski JM, [...] Bruner DW
J Clin Oncol 2023

Logistical, technical, and radiation safety aspects of establishing a radiopharmaceutical therapy program: A case in Lutetium-177 prostate-specific membrane antigen (PSMA) therapy.

Zoberi JE, Garcia-Ramirez J, Luechtefeld D, [...] Michalski JM
J Appl Clin Med Phys 2023

View All Publications

Contact Information

Washington University Medical Campus

4921 Parkview Place
Saint Louis, MO 63110

Phone Numbers

Appointments: (314) 747-7222
Toll Free: (800) 600-3606

Request an appointment